Leads, Technologies and Clinical Trials for New TB Drug Regimens

The Tuberculosis Drug Discovery and Development GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field.

Despite advances, Tuberculosis therapy still requires lengthy, complex treatment and available treatments for drug resistant TB can result in serious side effects. The Gordon Research Conference series on Tuberculosis Drug Discovery & Development has been making important contributions to the quest for new TB drugs for more than two decades. The key to the success of these conferences is their constant mission to bring together diverse and international researchers from all career stages and sectors and from all fields relevant to TB drug discovery and development, to present and discuss key topics and challenges inherent in this endeavor in a deliberately inclusive and collaborative environment. This focus has resulted in numerous fruitful discussions and connections, as well as promoting mentorship, the collegiality of the field and providing training for the next generation of researchers.

The 2023 Conference will feature presentations on breaking preclinical and clinical science followed by in-depth inclusive discussions. Extensive poster sessions will also feature, as well plentiful time for informal interactions during free time or over meals. The theme of the 2023 Conference - Leads, technologies, and clinical trials for new TB drug regimens - has been designed to combine cutting-edge research on clinical trial design, identification & development of new chemical matter, and translational research, with alternative approaches to treating TB and research that studies the biology of M. tuberculosis and TB disease, to improve TB chemotherapy. Each session is designed to address the challenges specific to the topic and will range from early stage drug discovery to lessons learned in clinical trials.

We invite researchers interested in all aspects of drug discovery and development and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from TB-endemic countries to apply, as their contribution to the struggle against TB is especially important. All participants are asked to submit abstracts of their work for presentation as posters, and some abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote extensive discussion. In the past, the meeting has been oversubscribed – please apply early!